Gyre Therapeutics, Inc. completed its acquisition of Cullgen Inc. on May 4, 2026, in an all-stock deal valued at approximately $300 million. This merger is intended as a tax-free reorganization, with key management changes and new stock plans implemented as part of the transaction.